Key result
RAS and AGEs pathway cross-talk influences diabetic retinopathy progression and offers new therapeutic targets.
Why the study?
The absence of an ideal therapy for diabetic retinopathy is due to incomplete understanding of the biochemical mechanisms and their impact on retinal cells.
What is the role of the renin-angiotensin system and advanced glycation end-products in diabetic retinopathy?
What is the role of the renin-angiotensin system and advanced glycation end-products in diabetic retinopathy?
Understanding the synergistic interactions between the renin-angiotensin system and advanced glycation end-products may lead to novel therapeutic strategies for diabetic retinopathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for dual RAS-AGE targeting in diabetic retinopathy; prospective trials needed before any practice consideration.
Diabetic retinopathy is a major cause of vision impairment and blindness and represents a significant health burden throughout the world. There is considerable interest in developing new treatments that retard the progression of diabetic retinopathy from its early to proliferative stages. It could be argued that the absence of an ideal therapy for diabetic retinopathy comes from an incomplete understanding about the biochemical mechanisms that underlie this disease, and their precise impact on specific retinal cell populations. Findings from pre-clinical and clinical studies indicate that both the renin-angiotensin system (RAS) and advanced glycation end-products (AGEs) influence various aspects of diabetic retinopathy. Of interest is growing evidence of cross-talk between the RAS and AGEs pathways. This review will discuss the role of both the RAS and AGEs in diabetic retinopathy, and how the identification of interactions between the two pathways may have implications for the development of new treatment strategies.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2013) conducted a review in Diabetic retinopathy. Renin-angiotensin system (RAS) and advanced glycation end-products (AGEs) was evaluated. The renin-angiotensin system and advanced glycation end-products pathways exhibit cross-talk that influences the progression of diabetic retinopathy, offering potential targets for new treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: